Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 5/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 5/20 | 0.55 |
| ▸ | PPARG | P37231 | 4/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073752 | 1.00 | ACE (0.63) | ACEABCB1BCL2ITGB3ITGA2B | |
| SCHEMBL2073423 | 0.92 | REN (0.57) | ACEABCB1BCL2CTSSCTSK | |
| SCHEMBL2073421 | 0.92 | REN (0.57) | ACEABCB1BCL2CTSSCTSK | |
| SCHEMBL2074420 | 0.91 | KLK5 (0.59) | ACEABCB1BCL2CTSSCTSK | |
| SCHEMBL2074421 | 0.91 | KLK5 (0.59) | ACEABCB1BCL2CTSSCTSK | |
| SCHEMBL27805737 | 0.88 | CTSK (0.57) | ACEABCB1BCL2CTSSCTSK | |
| SCHEMBL9955453 | 0.88 | ACE (0.59) | ACEABCB1BCL2ITGB3ITGA2B | |
| SCHEMBL66220 | 0.87 | ACE (0.79) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL795685 | 0.87 | ACE (0.79) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL21473784 | 0.87 | ACE (0.79) | ACEITGB3ITGA2BCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101945851-B | peptidyl nitriles and their use as dipeptidyl peptidase I inhibitors | ASTRAZENECA AB | 2012-10-31 | — | — | CN | disclosed |
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| CN-101945851-A | Peptidyl nitriles and their use as dipeptidyl peptidase I inhibitors | ASTRAZENECA AB | 2011-01-12 | — | — | CN | disclosed |
| EP-2231597-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009074829-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | ACE 1597/4885ABCB1 97/4885BCL2 2301/4885 |
| US-20110201581-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | ACE 1597/4885ABCB1 97/4885BCL2 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.